Suboptimal response to tumor necrosis factor antagonists in inflammatory bowel disease in Latin America: EXPLORE LATAM study-Reference-Cited by-同舟云学术

Suboptimal response to tumor necrosis factor antagonists in inflammatory bowel disease in Latin America: EXPLORE LATAM study

Published:2024-01 Issue:1 Volume:47 Page:51-62
ISSN:0210-5705
Container-title:Gastroenterología y Hepatología
language:en
Short-container-title:Gastroenterología y Hepatología

Author:

Balderramo Domingo,Yamamoto-Furusho Jesús,Ponce de León Enrique,de María Julio,Zubiaurre Ignacio,Pedreira Silvia,Lis Camilo,Brion Laura,de Paula Juan A.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference28 articles.

1. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies;Ng;Lancet,2017

2. Diagnosis and treatment of inflammatory bowel disease: First Latin American Consensus of the Pan American Crohn's and Colitis Organisation;Yamamoto-Furusho;Rev Gastroenterol Mex,2017

3. Progression of inflammatory bowel diseases throughout Latin America and the Caribbean: a systematic review;Kotze;Clin Gastroenterol Hepatol,2020

4. From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease;Randall;Therap Adv Gastroenterol,2015

5. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects;Allez;J Crohns Colitis,2010

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world experience of vedolizumab use in Colombian patients with inflammatory bowel disease—EXVEDOCOL;Gastroenterología y Hepatología;2024-02